Bulking Agent vs Sling for Stress Urinary Incontinence
(BASIS Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on stable medication for overactive bladder or urinary urgency incontinence, you should continue it without changes for at least 3 months before the trial and throughout the study period.
What data supports the effectiveness of the treatment Bulkamid Transurethral Bulking Agent for stress urinary incontinence?
Bulkamid, a gel used to treat stress urinary incontinence, has shown long-term effectiveness and safety, with studies reporting success rates between 64% and 74%. It is a minimally invasive option that creates a supportive mass in the urethra, and is often used when other treatments like midurethral slings are not suitable or have failed.12345
Is Bulkamid safe for treating stress urinary incontinence?
How is the Bulkamid Transurethral Bulking Agent and Solyx Single-incision Sling treatment different from other treatments for stress urinary incontinence?
The Bulkamid Transurethral Bulking Agent and Solyx Single-incision Sling treatment is unique because it combines a bulking agent, which is injected to add volume and support to the urethra, with a minimally invasive sling procedure that provides additional support to prevent urine leakage. This dual approach offers a less invasive alternative to traditional surgeries and may provide longer-lasting results compared to treatments that require frequent re-injections.89101112
What is the purpose of this trial?
This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care.The Primary Aim is to determine the comparative effectiveness (as defined by "much" or "very much" better on PGI-I) of transurethral bulking agent (TBA) \[for 1 or 2 injections in 12 months\] vs. single-incision sling (SIS) 12 months after treatment intervention in women with predominant stress urinary incontinence (SUI).
Research Team
Emily Lukacz, MD
Principal Investigator
University of California, San Diego
Marie Gantz, MD
Principal Investigator
RTI International
Eligibility Criteria
This trial is for women who have stress urinary incontinence (SUI) or mixed urinary incontinence with a stress component, and haven't found relief from conservative treatments. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and agree to follow the study procedures.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either transurethral bulking agent or single-incision sling as treatment for stress urinary incontinence
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Bulkamid Transurethral Bulking Agent
- Solyx Single-incision Sling
Bulkamid Transurethral Bulking Agent is already approved in European Union, United States, Canada for the following indications:
- Stress urinary incontinence
- Stress urinary incontinence
- Stress urinary incontinence
Find a Clinic Near You
Who Is Running the Clinical Trial?
NICHD Pelvic Floor Disorders Network
Lead Sponsor
Kaiser Permanente
Collaborator
RTI International
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
Duke University
Collaborator
University of Texas Southwestern Medical Center
Collaborator
University of Chicago
Collaborator
University of California, San Diego
Collaborator
University of Pennsylvania
Collaborator
Women and Infants Hospital of Rhode Island
Collaborator